To investigate if tumor-expressed SLAMF7 was a requisite for phagocytosis of DLBCL cells upon CD47 targeting, we generated type 1 macrophages (MØ) as the prototype pro-inflammatory macrophage subtype associated with anti-cancer activity. Here, SLAMF7 is linked to neoplasm.